

Drug resistance interpretation: PR		HNDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10I 99% <small>cons=3,293</small> • I13V 99% <small>cons=3,040</small> • L19I 99% <small>cons=4,117</small> • E35D 99% <small>cons=5,124</small> • M36I 99% <small>cons=5,123</small> • R41K 99% <small>cons=4,912</small> • R57K 99% <small>cons=4,242</small> • Q61H 100% <small>cons=4,239</small> • H69K 99% <small>cons=3,894</small> • K70R 99% <small>cons=3,894</small> • L89M 100% <small>cons=3,293</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none">L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.		

Mutation scoring: PR	HNDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT		HIVDB 9.5.1 (2023-11-05)	
NRTI Mutations:	None		
NNRTI Mutations:	E138A 99% cons=2,355		
RT Other Mutations:	V35T 100% cons=12,694 • V60I 100% cons=12,805 • K64R 99% cons=1,779 • D121H 99% cons=1,709 • K122E 100% cons=1,709 • I135T 100% cons=2,370 • I142T 99% cons=2,209 • Q145V 100% cons=2,210 • K173S 100% cons=3,205 • Q174K 99% cons=3,205 • D177E 100% cons=3,111 • I178M 99% cons=3,101 • V179I 99% cons=3,101 • T200A 99% cons=2,941 • Q207A 100% cons=2,312 • R211S 99% cons=2,837 • V245T 99% cons=178 • D250E 99% cons=454		
Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Potential Low-Level Resistance
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Low-Level Resistance
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		
RT comments			
NNRTI			
<ul style="list-style-type: none">E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal.			
Other			
<ul style="list-style-type: none">V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.			

Mutation scoring: RT	HNDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for NRTI.	

Drug resistance mutation scores of NNRTI:

[Download CSV](#)

Rule	DOR	EFV	ETR	NVP	RPV
E138A	0	0	10	0	15